The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: Systematic review and meta-analysis
Open accessAbstract
Background: The increased prevalence of diabetes in schizophrenia is partly attributed to antipsychotic treatment, in particular second-generation antipsychotics, but the evidence has not been systematically reviewed. Aims: Systematic review and meta-analysis comparing diabetes risk for different antipsychotics in people with schizophrenia. Method: We searched MEDLINE, PsycINFO, EMBASE, International Pharmaceutical Abstracts, CINAHL and Web of Knowledge until September 2006. Studies were eligible for inclusion if the design was cross-sectional, case-control, cohort or a controlled trial in individuals with schizophrenia or related psychotic disorders, where second-generation antipsychotics (defined as clozapine, olanzapine, risperidone and quetiapine) were compared with first-generation antipsychotics and diabetes was an outcome. Data were pooled using random effects inverse variance weighted meta-analysis. Results: Of the studies that met the inclusion criteria (n=14), 11 had sufficient data to include in the meta-analysis. Four of these were retrospective cohort studies. The relative risk of diabetes in patients with schizophrenia prescribed one of the second-generation v. first-generation antipsychotics was 1.32 (95% CI 1.15-1.51). There were insufficient data to include aripiprazole, ziprasidone and amisulpride in this analysis. Conclusions: There is tentative evidence that the second-generation antipsychotics included in this study are associated with a small increased risk for diabetes compared with firstgeneration antipsychotics in people with schizophrenia. Methodological limitations were found in most studies, leading to heterogeneity and difficulty interpreting data. Regardless of type of antipsychotic, screening for diabetes in all people with schizophrenia should be routine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
The environment and disease: association or causation?
Hill, A. B. (2015) · Journal of the Royal Society of Medicine · doi:10.1177/0141076814562718 · Cited by 7,285
The Environment and Disease: Association or Causation?
Hill, A. B. (1965) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591576505800503 · Cited by 6,974
(1958) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030470133 · Cited by 2,489
Amos, A. F., McCarty, D. J., & Zimmet, P. (1997) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199712)14:5+<s7::aid-dia522>3.0.co;2-r · Cited by 1,882
Systematic Reviews in Health Care: Meta‐Analysis in Context
(2001) · doi:10.1002/9780470693926 · Cited by 1,693
The Structured Clinical Interview for DSM-III-R (SCID): II. Multisite Test-Retest Reliability
Williams, J. B. W. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080038006 · Cited by 1,618
Cited by
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951
Self-citationCorrell, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Increasing off‐label use of antipsychotic medications in the United States, 1995–2008
Alexander, G. C., Gallagher, S. A., Mascola, A., Moloney, R. M., & Stafford, R. S. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2082 · Cited by 423
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 385
Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M. (2012) · Psychological Medicine · doi:10.1017/s003329171100105x · Cited by 332
Vancampfort, D., Correll, C. U., Wampers, M., Sienaert, P., Mitchell, A. J., De Herdt, A., Probst, M., Scheewe, T. W., & De Hert, M. (2014) · Psychological Medicine · doi:10.1017/s0033291713002778 · Cited by 317
Osborn, D. P., Wright, C. A., Levy, G., King, M. B., Deo, R., & Nazareth, I. (2008) · BMC Psychiatry · doi:10.1186/1471-244x-8-84 · Cited by 208
Nielsen, J., Skadhede, S., & Correll, C. U. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.78 · Cited by 207
Treatment with antipsychotics and the risk of diabetes in clinical practice
Kessing, L. V., Thomsen, A. F., Mogensen, U. B., & Andersen, P. K. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.076935 · Cited by 152
Rajkumar, A. P., Horsdal, H. T., Wimberley, T., Cohen, D., Mors, O., Børglum, A. D., & Gasse, C. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16040442 · Cited by 137
Takeuchi, H., Suzuki, T., Uchida, H., Watanabe, K., & Mimura, M. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.021 · Cited by 115
Cardiovascular aspects of antipsychotics
Raedler, T. J. (2010) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32833f46c9 · Cited by 89
Robinson, D. J., Hanson, K., Jain, A. B., Kichler, J. C., Mehta, G., Melamed, O. C., Vallis, M., Bajaj, H. S., Barnes, T., Gilbert, J., et al. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.04.009 · Cited by 73
Rotella, F., Cassioli, E., Calderani, E., Lazzeretti, L., Ragghianti, B., Ricca, V., & Mannucci, E. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.12.118 · Cited by 48
Smith, R. C., Leucht, S., & Davis, J. M. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5133-z · Cited by 41
The prevention of diabetes and cardiovascular disease in people with schizophrenia
Holt, R. I. G. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12443 · Cited by 37
“A large number of pharmaco-epidemiological studies have shown that people receiving antipsychotics have a higher prevalence of diabetes and that people receiving second generation antipsychotics have a small but increased risk of diabetes compared with those receiving first generation drugs (16, 17).”
ResultSelf-citationDiabetes, physical activity participation and exercise capacity in patients with schizophrenia
Vancampfort, D., De Hert, M., Sweers, K., De Herdt, A., Detraux, J., & Probst, M. (2013) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12077 · Cited by 34
Svendal, G., Fasmer, O. B., Engeland, A., Berk, M., & Lund, A. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-148 · Cited by 17
“Of probable greater importance is the ability of antipsychotics to induce diabetes [28].”
Background
Metadata
- Authors
- Smith, M., Hopkins, D., Peveler, R. C., Holt, R. I. G., Woodward, M., & Ismail, K.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2008-06
- Volume
- 192
- Issue
- 6
- Pages
- 406-411
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2126642792
- Cited by
- 275
- References
- 47
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.